A Double-Masked Comparison Of 0.1% Tacrolimus Ointment And 2% Cyclosporine Eye Drops As First Line Drugs in the Treatment of Vernal Keratoconjunctivitis

2017 ◽  
Vol 16 (6) ◽  
pp. 30-35
Author(s):  
Ekta Singla ◽  
Harsimran Singh ◽  
, Navreet Kaur ◽  
Sachin Walia
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
First Line ◽  
Tacrolimus Ointment

scholarly journals Tear Ferning Test and Pathological Effects on Ocular Surface before and after Topical Cyclosporine in Vernal Keratoconjunctivitis Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-11
Author(s):  
Marcella Nebbioso ◽  
Marta Sacchetti ◽  
Guia Bianchi ◽  
Anna Maria Zicari ◽  
Marzia Duse ◽  
...  
Keyword(s):  
Cell Density ◽  
Goblet Cell ◽  
Ocular Surface ◽  
Goblet Cells ◽  
Significant Alteration ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Before And After ◽  
Tear Ferning Test ◽  
Goblet Cell Density

Background. Vernal keratoconjunctivitis (VKC) is a rare ocular surface inflammatory disease that affects mainly boys in the first decade of life. Clinical observations show that it generally regresses spontaneously with the onset of puberty, but therapeutic measures must be taken before then to control the course of the disease. Purpose.To evaluate the role of the lacrimal mucous component in VKC patients and compare tear ferning test (TFT) modifications, MUC5AC levels in tears, and density of conjunctival goblet cells to clinical characteristics before and after treatment with cyclosporine A (CY) in eye drops. Methods. Forty-seven patients affected by VKC and 30 healthy subjects aged between 3 and 16 years of life were enrolled. All individuals were submitted to complete eye examination and skin prick test (SPT) for the most common allergens. Then, they were subjected to collection of the tears and to impression cytology to evaluate TFT, MUC5AC levels, and conjunctival goblet cell density, before and after treatment with CY in eye drops. Results. Comparing the VKC group vs. the control group at baseline, a significant alteration in the degree of the ferns was found, indicating a pathological condition of the lacrimal mucous layer. In addition, an increased number of goblet cells were observed in the patients. The concentration of lacrimal secretory mucins (MUC5AC) did not show significant differences between the 2 groups. Patients treated with CY have reported improvements of some signs and symptoms of disease activity, including TFT, and a tendency of conjunctival goblet cell density to normalise. Conclusions. The results obtained demonstrated for the first time a significant alteration of the lacrimal mucin component evaluated in the VKC group, and an improvement of the latter after CY therapy.

scholarly journals The Efficacy of 0.03% Dermatological Tacrolimus Ointment for Refractory Vernal Keratoconjunctivitis.

2020 ◽  
Vol 35 (4) ◽  
pp. 229-234
Author(s):  
Hafiza Sadia Imtiaz
Keyword(s):  
Clinical Symptoms ◽  
Clinical Signs ◽  
Vernal Keratoconjunctivitis ◽  
P Value ◽  
Baseline Score ◽  
Assessment Data ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Quasi Experimental ◽  
Written Informed Consent

  Purpose: To determine the efficacy of 0.03% dermatological tacrolimus ointment in patients with refractory vernal keratoconjunctivitis Study Design: Quasi-experimental study Study Place and Duration: Eye Department, DHQ-Teaching Hospital, Gujranwala, Pakistan from April 2018 to March 2019 Material and Methods: After approval from hospital ethical committee and obtaining written informed consent from each patient/guardian, patients of either gender between 4-16 years of age with VKC not responding to conventional treatment for more than 8 weeks or having steroid-induced complications were included in this study. Dermatological tacrolimus ointment 0.03% started to be placed in inferior fornix in BD frequency along with topical lubricants. Patients were followed up on a regular schedule. Individual symptoms score was assessed from the questionnaire and signs score from observer’s clinical assessment. Data were analyzed using SPSS v23.0. P-value <0.05 was considered as statistically significant. Results: 40 eyes of 20 patients were included in this study. Out of which 4(20%) were female and 16 were male (80%). Mean baseline score for clinical symptoms was 6.65±1.81 that reduced to 1.65±0.81 after 12 weeks treatment course of tacrolimus with a significant p-value of 0.006 (p<0.05). Mean baseline score for clinical signs was 5.9±1.59 that improved to 1.80±0.83 after 12 weeks treatment course with a statistically significant p-value of 0.003 (p<0.05). Conclusions: In conclusion, topical tacrolimus dermatological ointment 0.03% is highly effective in refractory VKC and can be safely used as an alternative in VKC patients who are steroid-responders.

Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis

2017 ◽  
Vol 59 (3) ◽  
pp. 126-134 ◽  
Author(s):  
Qi Wan ◽  
Jing Tang ◽  
Yu Han ◽  
Dan Wang ◽  
Hongquan Ye
Keyword(s):  
Therapeutic Effect ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops

PP-018 Preparation of eye drops for vernal keratoconjunctivitis: the pharmacist added to a team acts as a fulcrum between doctor and patient

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A123.3-A124
Author(s):  
V Borsi ◽  
C Sgromo ◽  
L Scala ◽  
G Scialino ◽  
A Calvani ◽  
...  
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Eye Drops

scholarly journals Treatment of allergic rhinoconjunctivitis: a review of the role of topical levocabastine

1995 ◽  
Vol 4 (7) ◽  
pp. S31-S38 ◽  
Author(s):  
R. Gerth van Wijk
Keyword(s):  
Adverse Effect ◽  
Sodium Cromoglycate ◽  
Nasal Spray ◽  
Allergic Rhinoconjunctivitis ◽  
Application Site ◽  
Eye Drops ◽  
Clinical Effects ◽  
Therapeutic Approaches ◽  
First Line ◽  
Duration Of Action

Lcocabastine is an extremely potent and highly selective H1-receptor antagonist which has been specifically developed as eye drops and nasal spray for the treatment of allergic rhinoconjunctivitis. Clinical experience to date suggests that this topical antihistamine is at least as effective as other current first-line therapeutic approaches for the treatment of this condition, including oral H1-receptor antagonists and sodium cromoglycate. Onset of action is rapid, with clinical effects apparent within minutes of instillation. Moreover, duration of action is sufficiently long to permit a convenient twice-daily dosing regimen. Topical levocabastine is well tolerated with an adverse-effect profile comparable with that of placebo and sodium cromoglycate. As might be expected from the route of drug administration, application site reactions are the most frequent adverse effect associated with levocabastine eye drops and nasal spray with an incidence comparable with that seen in placebotreated controls. The availability of effective and well-tolerated topical antihistamines, such as levocabastine, is an important advance which broadens the range of therapeutic approaches available for the clinical management of allergic rhinoconjunctivitis. Levocabastine appears to be an attractive alternative to oral antihistamines as a first-line therapeutic option for the treatment of this atopic condition.

scholarly journals Tacrolimus ointment for treatment of vernal keratoconjunctivitis

2016 ◽  
Vol 23 (1) ◽  
pp. 135 ◽  
Author(s):  
AbdulrahmanM Al-Amri ◽  
AleemGulzar Mirza ◽  
AhmedMossa Al-Hakami
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Tacrolimus Ointment

scholarly journals COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS

2021 ◽  
Vol 71 (1) ◽  
pp. 34-39
Author(s):  
Hassan Sajjad Rathore ◽  
Shahzad Saeed ◽  
Ahsan Mukhtar ◽  
Umar Ijaz ◽  
Asad Habib ◽  
...  
Keyword(s):  
Subjective Symptom ◽  
Military Hospital ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Subjective Symptoms ◽  
Cross Sectional ◽  
Group A ◽  
Objective Sign ◽  
The Mean ◽  
Group B

Objective: To compare the efficacy of tacrolimus 0.03% ointment to olopatadine 0.2% eye drops in the treatment of vernal keratoconjunctivitis. Study Design: Prospective cross-sectional study. Place and Duration of Study: Eye Department Combined Military Hospital Quetta, from Feb to Jul 2019. Methodology: A total of 69 patients with active vernal keratoconjunctivitis (VKC) were included in this study.Thirty six (52.17%) patients were randomized in tacrolimus group and 33 (47.83%) in olopatadine group B.Baseline values of the subjective symptom score (SSS) and the objective sign score (OSS) were noted. Patientswere reviewed on weeks 2, 4, 8 and 12 and the scores at each visit were summed. These scores were used forcomparison between groups. Results: At the start of the study, the mean subjective symptoms score and objective sign score of group A was 9.0 ± 2.04 and 3.93 ± 1.93 respectively, while that of group B was 8.88 ± 2.18 and 4.36 ± 1.90 respectively. At the end of 12-weeks, the mean subjective symptoms score and objective sign score of group A reduced to 0.11 ± 0.32 and 0.08 ± 0.28 respectively, while that of group B reduced to 1.70 ± 0.77 and 0.64 ± 0.55 respectively. Total improvement of scores (as a percentage of baselines) among tacrolimus group was 98.3% and olopatadine group was 83%. Conclusion: Although both 0.03% tacrolimus and 0.2% olopatadine were effective in improving the signs andsymptoms of VKC, 0.03% tacrolimus was significantly superior.

Sign in / Sign up

Export Citation Format

Share Document